IL6 and neoplasm: The inhibition of IL-6 by the use of an IL-6 antagonist, tocilizumab, or through shRNA, resulted in decreased tumor growth, reduced cancer stem cells (CSCs), and the suppression of colony formation in HER2+ and TNBC studies [82,84].